- Title
- Risk and outcomes of chemotherapy-induced diarrhea (CID) among patients with colorectal cancer receiving multi-cycle chemotherapy
- Creator
- Keefe, Dorothy M.; Elting, Linda S.; Nguyen, Hoang T.; Grunberg, Steven M.; Aprile, Giuseppe; Bonaventura, Antony; Selva-Nayagam, Sudarsha; Barsevick, Andrea; Koczwara, Bogda; Sonis, Stephen T.
- Relation
- Amgen
- Relation
- Cancer Chemotherapy and Pharmacology Vol. 74, Issue 4, p. 675-680
- Publisher Link
- http://dx.doi.org/10.1007/s00280-014-2526-5
- Publisher
- Springer
- Resource Type
- journal article
- Date
- 2014
- Description
- Background: Diarrhea is a common toxicity of chemotherapy, but the practice of reporting only severe grades (≥ 3) in clinical trials results in misleading conclusions of significance. Epidemiology remains poorly described, and effects of multi-cycle regimens have not been investigated. To better understand the risks, symptom burden and consequences of CID, we studied patients receiving chemotherapy for colorectal cancer (CRC). Methods: One hundred and fourteen patients receiving FOLFOX (95 patients, 530 cycles), FOLFOX + monoclonal antibodies (10 patients, 49 cycles) or FOLFIRI (9 patients, 50 cycles) were enrolled. CID was identified from diaries at baseline and daily during up to 8 chemotherapy cycles using supplemental questions on the Oral Mucositis Daily Questionnaire, a valid tool for collecting patient-reported outcomes of regimen-related mucosal injury. Patients scored CID severity from 0 “none” to 10 “worst possible,” and quantity from “little” to “severe” on a 5-point scale. Quality of life was measured using the FACT-G, and fatigue using the FACIT fatigue scale. Results: CID occurred in 89 % of patients on FOLFIRI, 50 % on FOLFOX + monoclonal antibodies and 56 % on FOLFOX alone. The risk of a first episode was highest during Cycle 1 (35 %) and dropped to <10 % during Cycles 3–5. Patients with CID reported poorer quality of life scores than those without CID (77.1 vs 80.7). Conclusions: Diarrhea occurs more commonly than typically appreciated during chemotherapy for CRC. Risk is highest during first exposure, suggesting variable susceptibility. Identification of this high-risk subgroup for prophylaxis could improve the quality of life.
- Subject
- chemotherapy-induced diarrhea; chemotherapy; colorectal cancer; patient-reported outcomes; quality of life
- Identifier
- http://hdl.handle.net/1959.13/1298247
- Identifier
- uon:19618
- Identifier
- ISSN:0344-5704
- Language
- eng
- Reviewed
- Hits: 5036
- Visitors: 4986
- Downloads: 0
| Thumbnail | File | Description | Size | Format |
|---|